Illumina, Inc. provides sequencing and array-based solutions for genetic and
genomic analysis. Its products and services serve customers in a range of
markets enabling the adoption of genomic solutions in research and clinical
settings for applications in the life sciences, oncology, reproductive health,
agriculture, and other emerging segments. The company provides instruments and
consumables used in genetic analysis; and genotyping and sequencing services,
instrument service contracts, and development and licensing agreements, as well
as cancer detection testing services. Its customers include genomic research
centers, academic institutions, government laboratories, and hospitals, as well
as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories,
and consumer genomics companies. The company markets and distributes its
products directly to customers in North America, Europe, Latin America, and the
Asia-Pacific region, as well as sells through life-science distributors in
various markets within Europe, the Asia-Pacific region, Latin America, the
Middle East, and Africa. The company was incorporated in 1998 and is based in
San Diego, California.
